Systematic review: GLP-1 agonists associated with reduced mortality and epigenetic aging markers in clinical trials.
This systematic review synthesizes evidence on GLP-1 receptor agonists as potential geroprotective agents. Clinical trials showed: SELECT trial found 19% reduction in all-cause mortality (HR 0.81) in obese patients without diabetes; FLOW trial showed 24% reduction in primary kidney composite endpoint (HR 0.76); and a 2025 semaglutide trial demonstrated significant deceleration of three DNA methylation aging clocks (DunedinPACE, PCGrimAge, PhenoAge) over 32 weeks. Mechanistic evidence links benefits to hypothalamic GLP-1 receptor signaling, AMPK/SIRT1 pathways, and microbiome-derived short-chain fatty acids.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 14, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Systematic review
- Sample size
- —
- Duration
- —
- Population
- Patients with obesity, with and without diabetes; diverse age groups
- Primary outcome
- All-cause mortality and modulation of validated DNA methylation aging clocks
- Effect size
- SELECT trial: 19% reduction in all-cause mortality (HR 0.81); FLOW trial: 24% reduction in primary kidney composite endpoint (HR 0.76); 32 weeks of semaglutide: significant deceleration of DunedinPACE, PCGrimAge, and PhenoAge
- Significance
- Significant
- Journal
- Experimental gerontology
- Published
- Sep 14, 2026
Sources
Primary source
- Experimental gerontology ↗Peer reviewed
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.